Rituximab in the Treatment of Epidermolysis Bullosa Acquisita: A Systematic Review

Overview

Journal J Clin Aesthet Dermatol

Date 2024 Jul 15

PMID 39006807

Authors

Nika Kianfar

Shayan Dasdar

Amir Marashi

Soheil Tavakolpour

Hamidreza Mahmoudi

Maryam Daneshpazhooh

Affiliations

Soon will be listed here.

Abstract

Objective: Epidermolysis bullosa acquisita (EBA) is a rare dermatosis of the mucous membrane and/or skin. Employing biologic treatment modalities, specifically rituximab (RTX), have become pivotal measure in treating patients with blistering diseases. This study aims to summarize the current evidence on the safety and efficacy of RTX in EBA.

Methods: An extensive search was performed in MEDLINE/PubMed, Embase, Scopus, and Web of Science databases until the end of August 19th, 2023. Two independent reviewers screened the papers, and collected data. Two hundred thirty-three studies were screened using Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines.

Results: Thirty-one studies were enrolled. The most common reason of RTX administration in patients with EBA was recalcitrant diseases. Clinical response and disease remission was recorded as 92.7 percent (63 patients) and 73.8 percent (45 patients) of the patients, respectively. A relapse rate of 39.5 percent (15 patients) in the mean follow-up of 23.0 months was reported in the studies. Of the patients, 28.2 percent (11 patients) experienced RTX-related side events, mostly mild and transient infusion reactions.

Conclusion: The results of this systematic review demonstrated that RTX is safe and effective in patients with EBA. This biological treatment modality can be routinely used in managing EBA.

References

Lamberts A, Euverman H, Terra J, Jonkman M, Horvath B . Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases. Front Immunol. 2018; 9:248. PMC: 5827539. DOI: 10.3389/fimmu.2018.00248. View

Crichlow S, Mortimer N, Harman K . A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita. Br J Dermatol. 2007; 156(1):194-6. DOI: 10.1111/j.1365-2133.2006.07596.x. View

Santi C, Gripp A, Roselino A, Mello D, Gordilho J, Marsillac P . Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita - Brazilian Society of Dermatology. An Bras Dermatol. 2019; 94(2 Suppl 1):33-47. PMC: 6544032. DOI: 10.1590/abd1806-4841.2019940207. View

Oktem A, Akay B, Boyvat A, Kundakci N, Erdem C, Bostanci S . Long-term results of rituximab-intravenous immunoglobulin combination therapy in patients with epidermolysis bullosa acquisita resistant to conventional therapy. J Dermatolog Treat. 2016; 28(1):50-54. DOI: 10.1080/09546634.2016.1179711. View

Schauer F, Nystrom A, Kunz M, Hubner S, Scholl S, Athanasiou I . Case Report: Diagnostic and Therapeutic Challenges in Severe Mechanobullous Epidermolysis Bullosa Acquisita. Front Immunol. 2022; 13:883967. PMC: 9021387. DOI: 10.3389/fimmu.2022.883967. View

Kubisch I, Diessenbacher P, Schmidt E, Gollnick H, Leverkus M . Premonitory epidermolysis bullosa acquisita mimicking eyelid dermatitis: successful treatment with rituximab and protein A immunoapheresis. Am J Clin Dermatol. 2010; 11(4):289-93. DOI: 10.2165/11533210-000000000-00000. View

Brassat S, Fleury J, Camus M, Monegier du Sorbier C, Guillet G . [Epidermolysa bullosa acquisita and graft-versus-host disease]. Ann Dermatol Venereol. 2014; 141(5):369-73. DOI: 10.1016/j.annder.2014.01.014. View

Koszegi B, Stone C, Ishii N, Hashimoto T, Murrell D . Sustained clinical remission for 5 years in severe epidermolysis bullosa acquisita following rituximab infusions. J Eur Acad Dermatol Venereol. 2024; 38(9):e747-e749. DOI: 10.1111/jdv.19863. View

Saha M, Cutler T, Bhogal B, Black M, Groves R . Refractory epidermolysis bullosa acquisita: successful treatment with rituximab. Clin Exp Dermatol. 2010; 34(8):e979-80. DOI: 10.1111/j.1365-2230.2009.03608.x. View

10.

Iwata H, Vorobyev A, Koga H, Recke A, Zillikens D, Prost-Squarcioni C . Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients. Orphanet J Rare Dis. 2018; 13(1):153. PMC: 6122731. DOI: 10.1186/s13023-018-0896-1. View

11.

Wallet-Faber N, Franck N, Batteux F, Mateus C, Gilbert D, Carlotti A . Epidermolysis bullosa acquisita following bullous pemphigoid, successfully treated with the anti-CD20 monoclonal antibody rituximab. Dermatology. 2007; 215(3):252-5. DOI: 10.1159/000106585. View

12.

Han J, Yook H, Bang C, Lee J, Park Y, Lee J . Refractory Epidermolysis Bullosa Acquisita with Chronic Graft-versus-Host Disease Successfully Treated with Rituximab. Ann Dermatol. 2023; 35(Suppl 1):S129-S131. PMC: 10608369. DOI: 10.5021/ad.20.332. View

13.

Li Y, Foshee J, Sontheimer R . Sustained clinical response to rituximab in a case of life-threatening overlap subepidermal autoimmune blistering disease. J Am Acad Dermatol. 2010; 64(4):773-8. DOI: 10.1016/j.jaad.2009.09.045. View

14.

Dasdar S, Kianfar N, Tavakolpour S, Balighi K, Mahmoudi H, Daneshpazhooh M . Rituximab for the treatment of epidermolysis bullosa acquisita: A large case series of 15 patients. J Dtsch Dermatol Ges. 2023; 21(7):779-784. DOI: 10.1111/ddg.15108. View

15.

Kim J, Lee S, Kim S . Successful treatment of epidermolysis bullosa acquisita with rituximab therapy. J Dermatol. 2012; 39(5):477-9. DOI: 10.1111/j.1346-8138.2011.01360.x. View

16.

Buijsrogge J, Diercks G, Pas H, Jonkman M . The many faces of epidermolysis bullosa acquisita after serration pattern analysis by direct immunofluorescence microscopy. Br J Dermatol. 2011; 165(1):92-8. DOI: 10.1111/j.1365-2133.2011.10346.x. View

17.

Le Roux-Villet C, Prost-Squarcioni C, Alexandre M, Caux F, Pascal F, Doan S . Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol. 2011; 147(7):843-9. DOI: 10.1001/archdermatol.2011.54. View

18.

Cavailhes A, Balme B, Gilbert D, Skowron F . [Successful use of combined corticosteroids and rituximab in the treatment of recalcitrant epidermolysis bullosa acquisita]. Ann Dermatol Venereol. 2009; 136(11):795-9. DOI: 10.1016/j.annder.2009.02.007. View

19.

Bevans S, Sami N . The use of rituximab in treatment of epidermolysis bullosa acquisita: Three new cases and a review of the literature. Dermatol Ther. 2018; 31(6):e12726. DOI: 10.1111/dth.12726. View

20.

Mercader P, Rodenas J, Pena A, Mascaro Jr J . Fatal Pseudomona pneumonia following rituximab therapy in a patient with epidermolysis bullosa acquisita. J Eur Acad Dermatol Venereol. 2007; 21(8):1141-2. DOI: 10.1111/j.1468-3083.2006.02127.x. View